Benjamin M Ellingson

List of Publications by Year
in descending order

215	9,670	38742 50	48315 88
papers	citations	h-index	g-index

215	215	215	11055
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Amineâ€weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. NMR in Biomedicine, 2023, 36, .	2.8	7
2	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). Brain Imaging and Behavior, 2022, 16, 239-251.	2.1	5
3	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro-Oncology, 2022, 24, 1020-1028.	1.2	12
4	Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. Neuro-Oncology, 2022, 24, 770-778.	1.2	28
5	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI. Scientific Reports, 2022, 12, 1078.	3.3	5
6	Recovery of Supraspinal Microstructural Integrity and Connectivity in Patients Undergoing Surgery for Degenerative Cervical Myelopathy. Neurosurgery, 2022, 90, 447-456.	1.1	2
7	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. Frontiers in Oncology, 2022, 12, 849993.	2.8	1
8	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology, 2022, 24, 1219-1229.	1.2	9
9	Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital â€œFlipbooksâ€•to Control Systems Theory. Neurotherapeutics, 2022, 19, 1855-1868.	4.4	1
10	Daily functioning in glioma survivors: associations with cognitive function, psychological factorsÂand quality of life. CNS Oncology, 2022, 11, CNS84.	3.0	2
11	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. Cancers, 2022, 14, 2520.	3.7	2
12	Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks. Tomography, 2022, 8, 1437-1452.	1.8	0
13	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2022, 40, TPS2078-TPS2078.	1.6	3
14	Characterizing malignant transformation in patients with IDH-mutant glioma.. Journal of Clinical Oncology, 2022, 40, 2065-2065.	1.6	0
15	Evaluation of the response assessment criteria in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2020-2020.	1.6	0
16	Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	1.6	10
17	A single-institution, retrospective examination of new contrast enhancement, progression, and pseudoprogression in IDH mutant glioma.. Journal of Clinical Oncology, 2022, 40, 2043-2043.	1.6	0
18	Incidence, molecular characteristics, and imaging features of â€œclinically-defined pseudoprogressionâ€• in newly diagnosed glioblastoma treated with chemoradiation. Journal of Neuro-Oncology, 2022, 159, 509-518.	2.9	8

#	Article	IF	Citations
19	Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro-Oncology, 2021, 23, 189-198.	1.2	11
20	Voxelwise and Patientwise Correlation of ¹⁸F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-NaÃ¯ve Diffuse Gliomas with Different Molecular Subtypes. Journal of Nuclear Medicine, 2021, 62, 319-325.	5.0	13
21	Influence of phosphate concentration on amine, amide, and hydroxyl CEST contrast. Magnetic Resonance in Medicine, 2021, 85, 1062-1078.	3.0	7
22	Minimizing echo and repetition times in magnetic resonance imaging using a double halfâ€echo k â€space acquisition and lowâ€rank reconstruction. NMR in Biomedicine, 2021, 34, e4458.	2.8	3
23	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. Neuroradiology, 2021, 63, 857-868.	2.2	7
24	A physical phantom for amine chemical exchange saturation transfer (CEST) MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, 34, 569-580.	2.0	2
25	Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab082.	0.7	2
26	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology, 2021, 23, 1056-1071.	1.2	68
27	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. Cancer Imaging, 2021, 21, 27.	2.8	13
28	Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. Radiotherapy and Oncology, 2021, 156, 258-265.	0.6	18
29	Preferential tumor localization in relation to 18F-FDOPA uptake for lowerâ€grade gliomas. Journal of Neuro-Oncology, 2021, 152, 573-582.	2.9	2
30	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clinical Cancer Research, 2021, 27, 3916-3925.	7.0	24
31	Detection of cerebral reorganization associated with degenerative cervical myelopathy using diffusion spectral imaging (DSI). Journal of Clinical Neuroscience, 2021, 86, 164-173.	1.5	7
32	ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma. Data in Brief, 2021, 35, 106950.	1.0	3
33	Cortical morphometric correlational networks associated with cognitive deficits in first episode schizophrenia. Schizophrenia Research, 2021, 231, 179-188.	2.0	6
34	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. Annals of Nuclear Medicine, 2021, 35, 1022-1029.	2.2	5
35	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clinical Cancer Research, 2021, 27, 4491-4499.	7.0	112
36	Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging. Scientific Reports, 2021, 11, 15011.	3.3	10

#	Article	IF	Citations
37	Supraspinal functional and structural plasticity in patients undergoing surgery for degenerative cervical myelopathy. Journal of Neurosurgery: Spine, 2021, , 1-9.	1.7	4
38	Sodium MR Neuroimaging. American Journal of Neuroradiology, 2021, 42, 1920-1926.	2.4	9
39	Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. Cancer Journal (Sudbury, Mass), 2021, 27, 395-403.	2.0	2
40	Sex-Dependent Cortical Volume Changes in Patients with Degenerative Cervical Myelopathy. Journal of Clinical Medicine, 2021, 10, 3965.	2.4	3
41	A study of 3D radial density adapted trajectories for sodium imaging. Magnetic Resonance Imaging, 2021, 83, 89-95.	1.8	1
42	Unique challenges for glioblastoma immunotherapyâ€"discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
43	Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021, 9, 236.	11.1	34
44	â€œAerobic glycolytic imagingâ€•of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. NeuroImage: Clinical, 2021, 32, 102882.	2.7	8
45	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro-Oncology, 2020, 22, 705-717.	1.2	47
46	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. Neuro-Oncology, 2020, 22, 694-704.	1.2	23
47	Compensatory brainstem functional and structural connectivity in patients with degenerative cervical myelopathy by probabilistic tractography and functional MRI. Brain Research, 2020, 1749, 147129.	2.2	14
48	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Scientific Reports, 2020, 10, 11922.	3.3	23
49	Focal cortical dysplasia imaging discrepancies between MRI and FDG-PET: Unique association with temporal lobe location. Seizure: the Journal of the British Epilepsy Association, 2020, 81, 180-185.	2.0	6
50	Response to Letter to Editor. Neuro-Oncology, 2020, 22, 1706-1707.	1.2	1
51	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naÃ¯ve diffuse gliomas. Journal of Neuro-Oncology, 2020, 149, 337-346.	2.9	5
52	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. Scientific Reports, 2020, 10, 14819.	3.3	13
53	Novel tonometer device distinguishes brain stiffness in epilepsy surgery. Scientific Reports, 2020, 10, 20978.	3.3	4
54	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. Neurosurgery, 2020, 87, 931-938.	1.1	14

#	Article	IF	Citations
55	Association between cortical volume and gray-white matter contrast with second generation antipsychotic medication exposure in first episode male schizophrenia patients. Schizophrenia Research, 2020, 222, 397-410.	2.0	10
56	Ivosidenib in Isocitrate Dehydrogenase 1â€“Mutated Advanced Glioma. Journal of Clinical Oncology, 2020, 38, 3398-3406.	1.6	167
57	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro-Oncology, 2020, 22, 1262-1275.	1.2	109
58	Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro-Oncology, 2020, 22, 1658-1666.	1.2	27
59	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. Journal of Neuro-Oncology, 2020, 147, 643-652.	2.9	5
60	Pathophysiology, classification, and MRI parallels in microvascular disease of the heart and brain. Microcirculation, 2020, 27, e12648.	1.8	6
61	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro-Oncology, 2020, 22, 757-772.	1.2	131
62	Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. Journal of Neuro-Oncology, 2020, 147, 135-145.	2.9	12
63	First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clinical Cancer Research, 2020, 26, 1820-1828.	7.0	54
64	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro-Oncology, 2020, 22, 1822-1830.	1.2	23
65	Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clinical Cancer Research, 2020, 26, 3135-3144.	7.0	7
66	Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas. Clinical Nuclear Medicine, 2020, 45, e505-e511.	1.3	4
67	The Path Forward: The Standardized Brain Tumor Imaging Protocol (BTIP) for Multicenter Trials. , 2020, , 267-282.		0
68	Contrast-Enhanced T1-Weighted Digital Subtraction for Increased Lesion Conspicuity and Quantifying Treatment Response in Malignant Gliomas. , 2020, , 49-60.		0
69	Early seizures and temporal lobe trauma predict post-traumatic epilepsy: A longitudinal study. Neurobiology of Disease, 2019, 123, 115-121.	4.4	91
70	Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. CNS Oncology, 2019, 8, CNS35.	3.0	7
71	Spinal Cord Perfusion MR Imaging Implicates Both Ischemia and Hypoxia in the Pathogenesis of Cervical Spondylosis. World Neurosurgery, 2019, 128, e773-e781.	1.3	32
72	Neck disability in patients with cervical spondylosis is associated with altered brain functional connectivity. Journal of Clinical Neuroscience, 2019, 69, 149-154.	1.5	9

#	Article	IF	Citations
73	On the promise of artificial intelligence for standardizing radiographic response assessment in gliomas. Neuro-Oncology, 2019, 21, 1346-1347.	1.2	3
74	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. American Journal of Neuroradiology, 2019, 40, 979-986.	2.4	24
75	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro-Oncology, 2019, 21, 1184-1196.	1.2	28
76	Probabilistic independent component analysis of dynamic susceptibility contrast perfusion MRI in metastatic brain tumors. Cancer Imaging, 2019, 19, 14.	2.8	7
77	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Scientific Reports, 2019, 9, 2846.	3.3	32
78	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 142, 587-595.	2.9	28
79	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine, 2019, 25, 477-486.	30.7	932
80	pH-weighted molecular MRI in human traumatic brain injury (TBI) using amine proton chemical exchange saturation transfer echoplanar imaging (CEST EPI). NeuroImage: Clinical, 2019, 22, 101736.	2.7	19
81	Advanced Imaging in the Evaluation of Migraine Headaches. Neuroimaging Clinics of North America, 2019, 29, 301-324.	1.0	20
82	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. Neuro-Oncology, 2019, 21, vi28-vi29.	1.2	17
83	Selective middle cerebral artery occlusion in the rabbit: Technique and characterization with pathologic findings and multimodal MRI. Journal of Neuroscience Methods, 2019, 313, 6-12.	2.5	4
84	Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. Neuro-Oncology Practice, 2019, 6, 103-111.	1.6	3
85	Alterations in Cortical Thickness and Subcortical Volume are Associated With Neurological Symptoms and Neck Pain in Patients With Cervical Spondylosis. Neurosurgery, 2019, 84, 588-598.	1.1	26
86	Understanding brain penetrance of anticancer drugs. Neuro-Oncology, 2018, 20, 589-596.	1.2	12
87	18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naÃ¯ve gliomas: a cross-sectional study. Journal of Neuro-Oncology, 2018, 139, 399-409.	2.9	32
88	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. Neuro-Oncology, 2018, 20, 1525-1535.	1.2	15
89	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro-Oncology, 2018, 20, 1411-1418.	1.2	24
90	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 1240-1250.	1.2	64

#	Article	IF	Citations
91	Simultaneous p<scp>H</scp>â€sensitive and oxygenâ€sensitive <scp>MRI</scp> of human gliomas at 3 <scp>T</scp> using multiâ€echo amine proton chemical exchange saturation transfer spinâ€andâ€gradient echo echoâ€planar imaging (<scp>CESTâ€SAGEâ€EPI</scp>). Magnetic Resonance in Medicine, 2018, 80, 1962-1978.	3.0	38
92	Disease-Related Microstructural Differences in the Brain in Women With Provoked Vestibulodynia. Journal of Pain, 2018, 19, 528.e1-528.e15.	1.4	15
93	Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging. American Journal of Neuroradiology, 2018, 39, 43-45.	2.4	15
94	Reproducibility, temporal stability, and functional correlation of diffusion MR measurements within the spinal cord in patients with asymptomatic cervical stenosis or cervical myelopathy. Journal of Neurosurgery: Spine, 2018, 28, 472-480.	1.7	16
95	Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Disease Pathophysiology and the Therapeutic Mechanism of Action of Antipsychotics. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 454-462.	1.5	18
96	Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro-Oncology, 2018, 20, 457-471.	1.2	44
97	Radiologic progression of glioblastoma under therapyâ€”an exploratory analysis of AVAglio. Neuro-Oncology, 2018, 20, 557-566.	1.2	24
98	Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study. PLoS ONE, 2018, 13, e0206807.	2.5	8
99	Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. Scientific Reports, 2018, 8, 14429.	3.3	22
100	Resting-State Functional Magnetic Resonance Imaging Connectivity of the Brain Is Associated with Altered Sensorimotor Function in Patients with Cervical Spondylosis. World Neurosurgery, 2018, 119, e740-e749.	1.3	23
101	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2018, 139, 651-659.	2.9	25
102	ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. PLoS ONE, 2018, 13, e0198548.	2.5	21
103	Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. Tomography, 2018, 4, 123-137.	1.8	16
104	HumanTERTpromoter mutation enables survival advantage fromMGMTpromoter methylation inIDH1wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-Oncology, 2017, 19, now189.	1.2	65
105	Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 228-234.	1.3	77
106	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics, 2017, 14, 307-320.	4.4	294
107	Evaluation of Encephaloduroarteriosynangiosis Efficacy Using Probabilistic Independent Component Analysis Applied to Dynamic Susceptibility Contrast Perfusion MRI. American Journal of Neuroradiology, 2017, 38, 507-514.	2.4	8
108	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade IIâ€“III diffuse gliomas. Journal of Neuro-Oncology, 2017, 134, 177-188.	2.9	118

#	Article	IF	Citations
109	Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. Journal of Neuro-Oncology, 2017, 134, 495-504.	2.9	160
110	Effects of MRI Protocol Parameters, Preload Injection Dose, Fractionation Strategies, and Leakage Correction Algorithms on the Fidelity of Dynamic-Susceptibility Contrast MRI Estimates of Relative Cerebral Blood Volume in Gliomas. American Journal of Neuroradiology, 2017, 38, 478-484.	2.4	39
111	Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas. European Journal of Radiology, 2017, 97, 31-36.	2.6	42
112	Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10220-10225.	7.1	79
113	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clinical Cancer Research, 2017, 23, 5745-5756.	7.0	53
114	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro-Oncology, 2017, 19, 89-98.	1.2	68
115	SU78. Intracortical Myelination Within the Frontal Lobe as a Potential Biomarker for Therapeutic Effectiveness in Antipsychotics Using MRI With Selective Myelin-Lipid Suppression at 1.5 and 3 T. Schizophrenia Bulletin, 2017, 43, S189-S189.	4.3	0
116	Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. American Journal of Neuroradiology, 2016, 37, 1440-1446.	2.4	39
117	Multisite, multimodal neuroimaging of chronic urological pelvic pain: Methodology of the MAPP Research Network. NeuroImage: Clinical, 2016, 12, 65-77.	2.7	29
118	Dynamic Susceptibility Contrast MR Imaging in Glioma. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 649-670.	1.1	43
119	Simulation, phantom validation, and clinical evaluation of fast pHâ€weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CESTâ€EPI) in glioma at 3â€‰T. NMR in Biomedicine, 2016, 29, 1563-1576.	2.8	51
120	Brain white matter changes associated with urological chronic pelvic pain syndrome: multisite neuroimaging from a MAPP caseâ€“control study. Pain, 2016, 157, 2782-2791.	4.2	43
121	Contrastâ€enhancing tumor growth dynamics of preoperative, treatmentâ€naive human glioblastoma. Cancer, 2016, 122, 1718-1727.	4.1	47
122	ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. Clinical Cancer Research, 2016, 22, 5079-5086.	7.0	99
123	Assessing variability in brain tumor segmentation to improve volumetric accuracy and characterization of change. , 2016, 2016, 380-383.		4
124	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)â€MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. Journal of Magnetic Resonance Imaging, 2016, 44, 1229-1237.	3.4	27
125	Topographical Distribution of Epileptogenic Tubers in Patients With Tuberous Sclerosis Complex. Journal of Child Neurology, 2016, 31, 636-645.	1.4	10
126	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clinical Cancer Research, 2016, 22, 575-581.	7.0	62

#	Article	IF	Citations
127	Pain and Interoception Imaging Network (PAIN): A multimodal, multisite, brain-imaging repository for chronic somatic and visceral pain disorders. NeuroImage, 2016, 124, 1232-1237.	4.2	26
128	Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma. Cancer Science, 2016, 107, 1110-1116.	3.9	16
129	Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients. Journal of the International Neuropsychological Society, 2015, 21, 868-879.	1.8	27
130	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. NeuroImage: Clinical, 2015, 9, 617-624.	2.7	23
131	Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. International Journal of Oncology, 2015, 46, 1883-1892.	3.3	57
132	NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI). Neuro-Oncology, 2015, 17, v158.4-v159.	1.2	70
133	Novel Magnetic Resonance Imaging Techniques in Brain Tumors. Topics in Magnetic Resonance Imaging, 2015, 24, 137-146.	1.2	2
134	Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas. Topics in Magnetic Resonance Imaging, 2015, 24, 127-136.	1.2	20
135	Unique Microstructural Changes in the Brain Associated with Urological Chronic Pelvic Pain Syndrome (UCPPS) Revealed by Diffusion Tensor MRI, Super-Resolution Track Density Imaging, and Statistical Parameter Mapping: A MAPP Network Neuroimaging Study. PLoS ONE, 2015, 10, e0140250.	2.5	64
136	DTI of tuber and perituberal tissue can predict epileptogenicity in tuberous sclerosis complex. Neurology, 2015, 85, 2011-2015.	1.1	33
137	A novel bicompartmental mathematical model of glioblastoma multiforme. International Journal of Oncology, 2015, 46, 825-832.	3.3	5
138	Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. Oncology Reports, 2015, 33, 2883-2888.	2.6	5
139	Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics. Current Neurology and Neuroscience Reports, 2015, 15, 506.	4.2	114
140	Nitroxoline induces apoptosis and slows glioma growth in vivo. Neuro-Oncology, 2015, 17, 53-62.	1.2	41
141	Brain White Matter Abnormalities in Female Interstitial Cystitis/Bladder Pain Syndrome: A MAPP Network Neuroimaging Study. Journal of Urology, 2015, 194, 118-126.	0.4	54
142	Patterns of brain structural connectivity differentiate normal weight from overweight subjects. NeuroImage: Clinical, 2015, 7, 506-517.	2.7	67
143	MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology, 2015, 122, 497-505.	2.9	37
144	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Molecular Imaging and Biology, 2015, 17, 434-442.	2.6	28

#	Article	IF	Citations
145	Correlation between degree of subvoxel spinal cord compression measured with super-resolution tract density imaging and neurological impairment in cervical spondylotic myelopathy. Journal of Neurosurgery: Spine, 2015, 22, 631-638.	1.7	25
146	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. Clinical Cancer Research, 2015, 21, 4373-4383.	7.0	27
147	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	10.7	582
148	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology, 2015, 17, 1514-1524.	1.2	96
149	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 2015, 17, 1188-98.	1.2	346
150	Standardized Brain Tumor Imaging Protocol for Clinical Trials. American Journal of Neuroradiology, 2015, 36, E65-E66.	2.4	4
151	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. CNS Oncology, 2015, 4, 247-256.	3.0	16
152	Advances in MR imaging for cervical spondylotic myelopathy. European Spine Journal, 2015, 24, 197-208.	2.2	47
153	Prediction of Neurological Impairment in Cervical Spondylotic Myelopathy using a Combination of Diffusion MRI and Proton MR Spectroscopy. PLoS ONE, 2015, 10, e0139451.	2.5	46
154	Diffusion MRI Characteristics after Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography, 2015, 1, 37-43.	1.8	12
155	Diffusion-Weighted Imaging of the Spinal Cord. , 2014, , 123-145.		6
156	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro-Oncology, 2014, 16, 414-420.	1.2	82
157	Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging, 2014, 14, 31.	2.8	21
158	Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro-Oncology, 2014, 16, vii24-vii35.	1.2	32
159	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro-Oncology, 2014, 16, vii36-vii47.	1.2	41
160	Emerging techniques and technologies in brain tumor imaging. Neuro-Oncology, 2014, 16, vii12-vii23.	1.2	41
161	Pros and cons of current brain tumor imaging. Neuro-Oncology, 2014, 16, vii2-vii11.	1.2	56
162	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. Neuro-Oncology, 2014, 16, v25-v25.	1.2	0

#	Article	IF	Citations
163	Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial. Radiology, 2014, 271, 200-210.	7.3	150
164	Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy. Clinical Cancer Research, 2014, 20, 3550-3559.	7.0	115
165	Regional and Voxelâ€Wise Comparisons of Blood Flow Measurements Between Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSCâ€MRI) and Arterial Spin Labeling (ASL) in Brain Tumors. Journal of Neuroimaging, 2014, 24, 23-30.	2.0	45
166	Diffusion tensor imaging predicts functional impairment in mild-to-moderate cervical spondylotic myelopathy. Spine Journal, 2014, 14, 2589-2597.	1.3	67
167	Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. Journal of Neuro-Oncology, 2014, 116, 373-379.	2.9	95
168	Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. Journal of Neuro-Oncology, 2014, 116, 551-558.	2.9	12
169	Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. Journal of Neuro-Oncology, 2014, 116, 601-608.	2.9	6
170	Imaging Techniques in Spinal Cord Injury. World Neurosurgery, 2014, 82, 1351-1358.	1.3	37
171	Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab.. Journal of Clinical Oncology, 2014, 32, 2007-2007.	1.6	3
172	Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. Journal of Neuro-Oncology, 2013, 112, 257-266.	2.9	13
173	Imaging biomarkers for antiangiogenic therapy in malignant gliomas. CNS Oncology, 2013, 2, 33-47.	3.0	17
174	Diffusion tensor imaging detects microstructural reorganization in the brain associated with chronic irritable bowel syndrome. Pain, 2013, 154, 1528-1541.	4.2	134
175	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. PET Clinics, 2013, 8, 201-217.	3.0	8
176	Magnetic Resonance Imaging of Glioma in the Era of Antiangiogenic Therapy. PET Clinics, 2013, 8, 163-182.	3.0	4
177	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology, 2013, 15, 370-381.	1.2	97
178	Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro-Oncology, 2013, 15, 626-634.	1.2	91
179	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. Neuro-Oncology, 2013, 15, 382-390.	1.2	38
180	Structural changes in functional gastrointestinal disorders. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 200-202.	17.8	7

#	Article	IF	Citations
181	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2012, 14, 333-343.	1.2	74
182	3â€²-Deoxy-3â€²-¹⁸F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab. Journal of Nuclear Medicine, 2012, 53, 29-36.	5.0	122
183	18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro-Oncology, 2012, 14, 1079-1089.	1.2	99
184	Diffusion Tensor Magnetic Resonance Tractography of the Prostate: Feasibility for Mapping Periprostatic Fibers. Urology, 2012, 80, 219-223.	1.0	34
185	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. NeuroImage, 2012, 59, 908-916.	4.2	128
186	Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)â€MRI estimates of cerebral blood volume (CBV) in human gliomas. Journal of Magnetic Resonance Imaging, 2012, 35, 1472-1477.	3.4	68
187	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Journal of Neuro-Oncology, 2012, 108, 491-498.	2.9	149
188	Nonlinear registration of diffusionâ€weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine, 2012, 67, 237-245.	3.0	36
189	Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology, 2012, 106, 111-119.	2.9	67
190	High Order Diffusion Tensor Imaging in Human Glioblastoma. Academic Radiology, 2011, 18, 947-954.	2.5	10
191	Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. Journal of Neuro-Oncology, 2011, 102, 95-103.	2.9	65
192	Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology, 2011, 105, 91-101.	2.9	33
193	Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy. Current Neurology and Neuroscience Reports, 2011, 11, 336-344.	4.2	98
194	Spatially quantifying microscopic tumor invasion and proliferation using a voxelâ€wise solution to a glioma growth model and serial diffusion MRI. Magnetic Resonance in Medicine, 2011, 65, 1131-1143.	3.0	42
195	3D visualization of subdural electrode shift as measured at craniotomy reopening. Epilepsy Research, 2011, 94, 102-109.	1.6	33
196	Editorial: Novel spinal cord imaging. Journal of Neurosurgery: Spine, 2011, 15, 645-647.	1.7	1
197	Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin. Journal of Clinical Oncology, 2011, 29, 4482-4490.	1.6	420
198	Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology, 2011, 13, 401-409.	1.2	95

#	Article	IF	Citations
199	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology, 2011, 13, 1151-1161.	1.2	69
200	Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. Journal of Neuro-Oncology, 2010, 97, 419-423.	2.9	17
201	Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. Journal of Magnetic Resonance Imaging, 2010, 31, 538-548.	3.4	240
202	High-resolution in vivo diffusion tensor imaging of the injured cat spinal cord using self-navigated, interleaved, variable-density spiral acquisition (SNAILS-DTI). Magnetic Resonance Imaging, 2010, 28, 1353-1360.	1.8	16
203	Lesion growth and degeneration patterns measured using diffusion tensor 9.4-T magnetic resonance imaging in rat spinal cord injury. Journal of Neurosurgery: Spine, 2010, 13, 181-192.	1.7	40
204	Morphology and Morphometry of Human Chronic Spinal Cord Injury Using Diffusion Tensor Imaging and Fuzzy Logic. Annals of Biomedical Engineering, 2008, 36, 224-236.	2.5	35
205	In vivo diffusion tensor imaging of the rat spinal cord at 9.4T. Journal of Magnetic Resonance Imaging, 2008, 27, 634-642.	3.4	27
206	Ex vivo diffusion tensor imaging and quantitative tractography of the rat spinal cord during longâ€term recovery from moderate spinal contusion. Journal of Magnetic Resonance Imaging, 2008, 28, 1068-1079.	3.4	45
207	Diffusion tensor magnetic resonance imaging in spinal cord injury. Concepts in Magnetic Resonance Part A: Bridging Education and Research, 2008, 32A, 219-237.	0.5	9
208	Characteristics of Mid- to Long-Latency Spinal Somatosensory Evoked Potentials following Spinal Trauma in the Rat. Journal of Neurotrauma, 2008, 25, 1323-1334.	3.4	6
209	Somatosensory Functional Correlates of Spinal Cord Diffusion Tensor Imaging during Long-term Recovery from Spinal Contusion. Neurosurgery, 2008, 62, 1411-1412.	1.1	2
210	Functional correlates of diffusion tensor imaging in spinal cord injury. Biomedical Sciences Instrumentation, 2008, 44, 28-33.	0.2	30
211	Gray and White Matter Delineation in the Human Spinal Cord Using Diffusion Tensor Imaging and Fuzzy Logic. Academic Radiology, 2007, 14, 847-858.	2.5	22
212	Optimal diffusion tensor indices for imaging the human spinal cord. Biomedical Sciences Instrumentation, 2007, 43, 128-33.	0.2	2
213	Morphology and Morphometry in Chronic Spinal Cord Injury Assessed Using Diffusion Tensor Imaging and Fuzzy Logic. , 2006, 2006, 1885-8.		15
214	A new technique for imaging the human spinal cord in vivo. Biomedical Sciences Instrumentation, 2006, 42, 255-60.	0.2	9
215	Morphology and Morphometry in Chronic Spinal Cord Injury Assessed Using Diffusion Tensor Imaging and Fuzzy Logic. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0